View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
July 11, 2018

Catabasis to initiate POLARIS DMD trial of edasalonexent

Catabasis Pharmaceuticals is set to commence the Phase lll POLARIS DMD trial in the second half of this year.

Catabasis Pharmaceuticals is set to commence the Phase lll POLARIS DMD trial in the second half of this year.

The trial is designed to examine the efficacy and safety of edasalonexent for the treatment of patients with Duchenne muscular dystrophy (DMD).

As part of the global, randomised, double-blind, placebo-controlled trial, around 125 patients aged between four and seven years are expected to be enrolled.

The enrolled patients will include various mutation types, along with individuals who have not been on steroids for at least six months.

Catabasis also expects to include boys on a stable dose of eteplirsen in the POLARIS DMD trial.

During the course of the trial, two boys will be treated with edasalonexent for every boy that receives placebo and after 12 months, all boys are expected to receive edasalonexent in an open-label extension.

The trial’s primary efficacy endpoint will be change in the North Star Ambulatory Assessment score after 12 months of treatment with edasalonexent compared to placebo.

“We believe that edasalonexent has great potential as a therapy to be taken on its own, as well as in combination with other treatments.”

Major secondary endpoints of the trial are expected to comprise the age-appropriate timed function tests time to stand, four-stair climb and 10m walk/run.

In addition, assessments of growth, cardiac and bone health are planned to be included.

Top-line results from the trial are expected in the second quarter of 2020.

Catabasis Pharmaceuticals chief medical officer Joanne Donovan said: “We have designed a robust study with POLARIS DMD to evaluate edasalonexent as a potential new treatment for Duchenne.

“We have benefitted from input from many people that are part of the Duchenne community and we are well underway with our preparations to begin the trial.

“We believe that edasalonexent has great potential as a therapy to be taken on its own, as well as in combination with other treatments.”

Edasalonexent is currently being developed as a potential oral foundational therapy for DMD patients.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU